You are here

Article info

Article menu

Download PDFPDF

Research Article
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Authors

  1. ↵a (732) 235-7563 howard.kaufman{at}rutgers.edu
  2. ↵b Robert.Andtbacka{at}hci.utah.edu
  3. ↵c frances_collichio{at}med.unc.edu
  4. ↵d wolfm{at}amgen.com
  5. ↵e zhongyun{at}amgen.com
  6. ↵f mark.shilkrut{at}gmail.com
  7. ↵g Igor.Puzanov{at}RoswellPark.org
  8. ↵h mross{at}mdanderson.org
View Full Text

Citation

Kaufman HL, Andtbacka RHI, Collichio FA, et al
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Journal for ImmunoTherapy of Cancer 2017;5:72. doi: 10.1186/s40425-017-0276-8

Publication history

  • Received May 4, 2017
  • Accepted August 14, 2017
  • First published September 19, 2017.
Online issue publication 
September 19, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.